Financials in USD. Standardized financial statements.
A compact view of how XTL Biopharmaceuticals Ltd. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $451,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $448,000 | $0 | $1,000 | $1,000 | $1,000 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $3,000 | $0 | -$1,000 | -$1,000 | -$1,000 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | +0.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $2.17M | $765,000 | $880,000 | $1.03M | $948,000 | $842,000 | $793,000 | $1.25M | $1.71M | $2.00M |
| Operating Income? | -$2.17M | -$765,000 | -$880,000 | -$1.03M | -$948,000 | -$842,000 | -$793,000 | -$1.25M | -$2.56M | -$3.61M |
| EBITDA? | -$930,000 | -$764,000 | -$879,000 | -$1.03M | -$947,000 | $0 | -$792,000 | -$1.25M | -$1.71M | -$2.00M |
| Income Before Tax | -$1.16M | -$1.78M | -$1.35M | $435,000 | -$2.95M | -$1.35M | $2.99M | -$781,000 | -$2.54M | -$3.62M |
| Income Tax Expense | -$130,000 | $0 | $0 | $0 | $0 | -$69,000 | -$80,000 | $0 | $0 | $0 |
| Net Income? | -$1.03M | -$1,782 | -$1.35M | $435,000 | -$782,000 | -$1.35M | $2.99M | -$781,000 | -$2.54M | -$4.31M |
| EPS? | $-9.60 | $0.00 | $-16.00 | $5.12 | $-36.48 | $-16.64 | $37.12 | $-10.88 | $-59.52 | $-104.32 |
| Diluted EPS? | $-9.60 | $0.00 | $-16.00 | $4.48 | $-36.48 | $-16.64 | $37.12 | $-10.88 | $-59.52 | $-104.32 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality